Eribulin (Halaven) as third- or late- line mono-therapy for advanced/metastatic breast cancer
Mathis S, Alberti C, Czeczot J, Garbaty T, Maran PR, Nachtnebel A
Record ID 32011001041
English
Authors' recommendations:
Eribulin is a valuable option in a patient group with limited therapeutic options. Due to a lack of information regarding quality of life the net benefit for patients remain partly unclear.
Details
Project Status:
Completed
URL for project:
http://eprints.hta.lbg.ac.at/927
Year Published:
2011
URL for published report:
n/a
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Austria
MeSH Terms
- Breast Neoplasms
- Ketones
- Neoplasm Metastasis
- Furans
Contact
Organisation Name:
Ludwig Boltzmann Institute for Health Technology Assessment
Contact Address:
Ludwig Boltzmann Institute for fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7/rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99
Contact Name:
tarquin.mittermayr@aihta.at
Contact Email:
office@aihta.at
Copyright:
Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.